Who am I? A Brief Bio PhD with John Schrader at The Biomedical Research Centre (UBC) Undergrad at Simon Fraser University Genetics: 3 summers in a Drosophila.

Slides:



Advertisements
Similar presentations
Cancer Research UK strategy and funding Simon Vincent.
Advertisements

NIHR Delivering Better Health 20 November 2012, Leeds Dr David Cox Deputy Director – Research Finance & Programmes.
Health Promotion.
The Clinic for Special Children Where compassion, care, and bioinformatics result in cutting edge translational medicine.
Spark NH Council Member Survey October – November, 2012.
Health, Disease and Survival The Essex Biomedical Sciences Institute Essex Biomedical Sciences Institute Dr Beverley Wilkinson Department of Biological.
Develop and Utilize Human Potential 1. Qatar Research Institutes.
Biotechnology and Medicine Prof. S.K.Panda Department of Pathology All India Institute of Medical Sciences.
Department of Medicine Task Force on Research. Committee Charge  Develop a unifying vision to become leaders in translational research Achieve top 10.
NHLBI Strategic Visioning Process: Charting Our Future Together
PHASE 1 Facilitating discussion on treatment preferences and advance care planning in cancer patients using the vignette technique Funding: Department.
10 th October 2013 The delivery of 21 st century services – the implications for the evolution of the Healthcare Science workforce Joan Fletcher.
Evdokia Anagnostou, MD Clinician Scientist, Holland Bloorview Kids Rehab Hospital Associate Professor, Department of Pediatrics University of Toronto Canada.
Successor to the Strategy for Science, Technology and Innovation HRB and Department of Health Consultation Workshop 11 March 2015 Dermot Curran Assistant.
Community Level Interventions
Module 2 Sealy Center on Aging What kinds of scholarly products can I produce?
Getting into Research PCH General Meeting. Why do research? Why is it important? Fun! Avenue to practice what you learned in class Way to personalize.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
The NIH Roadmap for Medical Research
Institute of Cancer Research - Institut du cancer ICR’s Activities in Cancer Imaging.
A Doctoral Curriculum in Transition Shoumita Dasgupta, Ph.D. A Case Study of Boston University’s Graduate Medical Sciences Curriculum Reform.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Challenge and Innovation in Cardiovascular Therapeutics: 1st Annual BHF Centre Symposium Michael D. Schneider MD FMedSci Head, National Heart and Lung.
Why the Alliance was Formed Rising rates of overweight and obesity; 50% of adults are not active enough for health benefits; Concern about dietary practices.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
Pre Med III Genetics Guri Tzivion, PhD Extension 506 Summer 2015 Windsor University School of Medicine.
Recognition Of Team Science Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth “Recognition by peers as an investigator.
UWA, COVS and LEI COVS is effectively the academic arm of LEI through which competitive research grants are managed and to which academic appointments.
Fungal Research Trust activities Aim to Build a Centre of Excellence – Direct research support – Direct clinical fungal lab support – Postgraduate training.
Safe and Effective Medicine for Children Daring to be Rare, BIOTECanada Panel 2015 CADTH Symposium Saskatoon, April
Specialist leaders of education Briefing session for potential applicants 2014.
Pharmacy Practice Model Initiative
The Need for Training on Team and Meeting Management to Enhance Capacity for Team Science Kady Nearing, Senior Evaluator The Evaluation Center Colorado.
Experience in Other Provinces: Nova Scotia Stroke System Neala Gill, RN, BN, MA Cardiovascular Health Nova Scotia Quebec Summit on Stroke October 7, 2008.
Medical Education Paul J. McDermott, Ph.D. Associate Dean for Faculty Affairs and Development Office:
Predictive Health and Society Health is the essential infrastructure for all that humans are capable of being doing or becoming individually or together.
Welcome. Brief introductions Opportunities that await Process of theme building Establishing the Theme NAME Next steps.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Center for Biomedical Imaging at Stanford (CBIS) Survey Department of Radiology March 4, 2008.
Public Population Projects in Genomics International Working Groups Working Meeting September th, 2005, Hinxton, UK.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
Foundation Doctors’ Academic Meeting Kathryn Adcock Wellcome Trust March 2011.
One Room, Many Doors: Logistics of Recruiting and Training Students in Neuroscience through an Undifferentiated Biomedical Program.
About the Clinical Immunology Society Established in 1986; Key inter-disciplinary organization for the field of clinical immunology and is devoted to fostering.
Dr Michelle Webb Renal Consultant, Associate Medical Director Patient Safety, East Kent Hospitals University NHS Foundation Trust and Co-lead for Sepsis.
Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Genome British Columbia November 18, 2015 / West Vancouver, BC.
Doug Brutlag 2011 The impact of genomics on the future of medicine and health Muhammad Faisal 2015-Arid-3638 PhD(scholar) Biochemistry.
Beating the Collaboration Blues – the Story of Two Community Mental Health Teams Funded by: Health Canada and AB Health & Wellness March 4, 2011, Saskatoon.
Over 150 Faculty Members Outstanding Graduate Training $27,000/year + $1000 allocation Excellent Health Benefits Tuition Waiver FREE Online Application.
Bringing Genomics Home Your DNA: A Blueprint for Better Health
Building chronic disease registries from EMR and administrative data
Biomedical Data Science for Precision Medicine
About the Clinical Immunology Society
The guiding principles of prudent healthcare
Rare Disease Scholar’s Program: Equipping the Next Generation of Rare Disease Clinical Researchers to Be Successful Good morning. Thank you for having.
EU funding opportunities
National and International Efforts worth knowing about
ISARIC – INTERNATIONAL SEVERE ACUTE RESPIRATORY INFECTION CONSORTIUM
Department of Medicine Michael Farkouh, Vice-Chair Research michael
Research for all Sharing good practice in research management
Clinical Genomics in Inflammatory Bowel Disease
12th – 13th November GRANADA
Bio-Rad Overview and Statement of Interests
STRATEGIC PLAN.
Center for Clinical and Translational Science
Presentation transcript:

Who am I? A Brief Bio PhD with John Schrader at The Biomedical Research Centre (UBC) Undergrad at Simon Fraser University Genetics: 3 summers in a Drosophila genetics lab Biochemistry: Cytokine signal transduction PDF with Maria Grazia Roncarolo at the Telethon Institute for Gene Therapy (TIGET-HSR) in Milano Cellular immunology: cell and gene therapy 2003 UBC Department of Surgery (transplant immunology) and VCHRI 2010 Moved to CFRI to join the Diabetes & Immunology Clusters

What is my area of research? how do Tregs normally work? can we find “biomarkers” to track the function of Tregs in patients can Tregs be given back as a cellular therapy to restore immune regulation? how can Tregs become dysfunctional and contribute to diseases? Primary immunodeficiencies, transplantation (organs & stem cells), diabetes, obesity, Inflammatory bowel disease, other autoimmune diseases….

Why did I accept this position? I love working at CFRI Great colleagues Core support (RTOD, training, core facilities etc) Amazing opportunities for research & impact Want to “give back” and contribute towards: -enabling research across the campus -the evolution of CFRI into internationally-known research institute -making CFRI an even more dynamic and fun place to work

CFRI Strategic Framework The combined activities of all the groups within a theme should enable the over-arching institute goals: 1.Increase research capacity 2.Increase research excellence 3.Impact on children’s health

Childhood Disorders Theme includes Groups that are focused on studying childhood diseases and disorders. focus on understanding mechanisms of health versus disease, as well as identifying and testing new diagnostic and therapeutic approaches.

Theme Opportunities Specific goals to be defined during the planning process, some initiatives to explore: Increase national & international recognition - Support participation in international conferences - Start a new theme level seminar series Enable investigator-initiated clinical trials -Interventional (therapies) & observational (biomarkers & diagnostics)

Theme Opportunities Facilitate multi-disciplinary research - Enable cross-group interactions Support existing and new cores/platforms Training in translational research (not only for trainees) - Biobanking - iPS cells - Exome sequencing and bioinformatics - Humanized mouse models, other model organisms - Standardized immune monitoring

As of May 4 th : 52 PIs selected Childhood Disorders as their primary theme (35% of respondents) Purpose of today: start the transition from clusters to groups under over arching themes 145 out of ~300 CFRI members responded to the visioning survey Of the 300 CFRI members: 232 are on site 152 hold funding with CFRI as primary institution Aim is for this to be a “grass roots” process

The Main Task ahead: defining “groups” A group is: ~10-20 investigators who want to work together because they see the potential benefit for themselves and the success of a larger program of research  Enable research in the context of a large scale funding opportunities (Foundations, CIHR-SPOR, Genome Canada, CFI, etc)  Optimize the potential for multi-disciplinary Research, training and mentoring in a common area of research  Optimize the development, implementation and use of a common technology (e.g. immune monitoring, iPS cells, imaging) some examples of reasons to form a group:

Keep in mind as we begin to define groups Groups are dynamic and meant to evolve Groups can cross themes Each group will have a leader Type 1 activity: feasible with current resources Each group will outline specific activities they wish to accomplish: Type 2 activity: made possible with new resources

Possible Groups Michael Cuccione Childhood Cancer Childhood Cancer Childhood cancer and blood disorders Cancer and Blood Research Childhood Cancer and Blood Research CancerDiabetes Childhood Obesity & Cardiometabolic Disease Diabetes ~ 30 groups suggested on the visioning web site

Possible Groups Variations on infection & immunity in kids Childhood Immunity Infectious Diseases Inflammatory disorders Primary Immune Deficiency Diseases Chronic Inflammatory Diseases Rheumatology Research Unit CUPIC

Possible Groups Pediatric Transplantation Cell therapy and transplantation Cell and Gene Therapy Variations on therapies Therapeutic discovery Variations on rare diseases Rare Diseases Systems Biology and Rare Disease Translational Research Hub for Rare Mendelian Disease

Other Group Suggestions Mechanisms of Disease - cross-cutting groups? Theme level activity? Surgery - how to best group surgeons (critical aspect of disease research [e.g. biobanking] and many therapeutic approaches [e.g. transplantation]) Obstructive Sleep Disorders - where to place specific diseases/disorders that fall outside large grouping (need to understand approaches and what is needed to enable research) How best to group other suggestions:

What will happen from here ? 1. Series of facilitated focus sessions with the goal of: 2. Facilitated session with group leads to: - Formalizing groups and identifying group leads - Identifying the first type 1 (possible now) and type 2 (possible with more resources) activities - Define theme level initiatives / goals - Ensure we do not re-create cluster “silos” - Ensure we do not have theme “silos”